1. A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture Elution 
Talia M. Muram, John H. Sloan, Jana S. Chain, Wendy J. Komocsar, Bruce I. Meiklejohn, Andrew Blauvelt, Kim Papp, Michael P. Heffernan, Yue-Wei Qian, Robert J. Konrad 
Journal of Investigative Dermatology 
Volume 136, Issue 7, Pages (July 2016)
DOI: /j.jid
Copyright © 2016 The Authors Terms and Conditions

2. Figure 1
Sensitivity of ACE assay compared with MSD bridging assay. Affinity-purified anti-ixekizumab antibody from monkeys or humans was spiked into normal human serum at concentrations ranging from ng/m. Samples were analyzed on the ACE and MSD bridging assays, with results shown as the mean ± SEM (n = 2). The MSD bridging assay reports in ECL units (ECLU), while the ACE assay generates an OD450 readout. Ab, antibody; ACE, affinity capture elution; ECLU, electrochemiluminescent units; MSD, Meso Scale Discovery; MSDB, Meso Scale Discovery bridging; OD450, optical density at 450 nanometers.
Journal of Investigative Dermatology  , DOI: ( /j.jid )
Copyright © 2016 The Authors Terms and Conditions

3. Figure 2
Drug tolerance of ACE assay compared with MSD bridging assay. Affinity-purified anti-ixekizumab antibody from monkeys or humans was spiked into normal human serum at a concentration of 500 ng/ml. Samples were also spiked with concentrations of ixekizumab ranging from 0.1–500.0 μg/ml and analyzed on the ACE and MSD bridging assays. Results are shown as the mean ± standard error of the mean (n = 2). The MSD bridging assay is reported in ECLUs, whereas the ACE assay generates an OD450 readout. Ab, antibody; ACE, affinity capture elution; ECLU, electrochemiluminescent units; MSD, Meso Scale Discovery; MSDB, Meso Scale Discovery bridging; OD450, optical density at 450 nanometers.
Journal of Investigative Dermatology  , DOI: ( /j.jid )
Copyright © 2016 The Authors Terms and Conditions